"Die Gautinger Lungenklinik ist ein vom Bayerischen Gesundheitsministerium offiziell anerkanntes Lungenzentrum, das überregional besondere Aufgaben in der Behandlung von Lungenerkrankten übernimmt und als Kompetenz- und Koordinierungszentrum andere medizinische Versorger mit gebündelter interdisziplinärer Fachexpertise berät. Mit 268 Betten und jährlich über 10.000 stationär behandelten Patienten ist sie die größte Lungenklinik in Bayern und zählt zu den fünf führenden Lungenkliniken bundesweit. Die Fachklinik ist Lehrkrankenhaus der Ludwig-Maximilians-Universität München und Gründungsmitglied des Comprehensive Pneumology Centers (CPC) sowie eine der wenigen außeruniversitären Lungenkliniken im Deutschen Zentrum für Lungenforschung (DZL)."

During the past decade, Asklepios Fachkliniken München-Gauting conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 15 clinical trials were completed, i.e. on average, 36.6% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 11 clinical trials were completed. i.e. 45.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Asklepios Fachkliniken München-Gauting" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Celgene" with 3 trials sponsored, "Daiichi Sankyo, Inc." with 3 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Asklepios Fachkliniken München-Gauting" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "PneumRx, Inc." with 2 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Asklepios Fachkliniken München-Gauting" are "Non-Small Cell Lung Cancer" (9 trials), "Non-small Cell Lung Cancer" (8 trials), "Carcinoma, Non-Small-Cell Lung" (6 trials), "Emphysema" (2 trials) and "Pulmonary Emphysema" (2 trials). Many other conditions were trialed in "Asklepios Fachkliniken München-Gauting" in a lesser frequency.

Most popular intervention types in "Asklepios Fachkliniken München-Gauting" are "Drug" (51 trials), "Device" (5 trials), "Other" (5 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (17 trials), "Pemetrexed" (10 trials), "Placebo" (10 trials), "Atezolizumab" (7 trials) and "Cisplatin" (7 trials). Other intervention names were less common.

The vast majority of trials in "Asklepios Fachkliniken München-Gauting" are 56 trials for "All" genders.

Currently, there are NaN active trials in "Asklepios Fachkliniken München-Gauting". undefined are not yet recruiting, 13 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Asklepios Fachkliniken München-Gauting, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Asklepios Fachkliniken München-Gauting, 3 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".